Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Composition ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "399874"] ; # fhir:meta [ fhir:versionId [ fhir:v "5" ] ; fhir:lastUpdated [ fhir:v "2025-12-11T20:35:21.032Z"^^xsd:dateTime ] ; ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 399874</b></p><a name=\"399874\"> </a><a name=\"hc399874\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-outcome-measure-report.html\">OutcomeMeasureReport</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/399874\">https://fevir.net/resources/Composition/399874</a></p><p><b>identifier</b>: FEvIR Object Identifier/399874, FEvIR Linking Identifier/NCT03421379-adverse-events-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 OutcomeMeasureReport}\">Outcome Measure Report</span></p><p><b>date</b>: 2025-12-11 20:35:21+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Adverse Events Report for NCT03421379</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Adverse Events Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399874. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399874. Computable resource at: https://fevir.net/resources/Composition/399874#json.</p>\n</div></td></tr></table><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-AllCauseMortality</b></p><a name=\"399874/NCT03421379-AllCauseMortality\"> </a><a name=\"hc399874/NCT03421379-AllCauseMortality\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: All-cause mortality (timeframe for NCT03421379)</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">All-cause mortality</span></td></tr></table><p><b>handling</b>: boolean variable</p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-SeriousAdverseEvents</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvents\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvents\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Serious Adverse Events (timeframe for NCT03421379)</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Serious Adverse Events</span></td></tr></table><p><b>handling</b>: boolean variable</p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvents</b></p><a name=\"399874/NCT03421379-OtherAdverseEvents\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvents\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Other Adverse Events (timeframe for NCT03421379)</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Other Adverse Events</span></td></tr></table><p><b>handling</b>: boolean variable</p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-AllCauseMortality-EG000</b></p><a name=\"399874/NCT03421379-AllCauseMortality-EG000\"> </a><a name=\"hc399874/NCT03421379-AllCauseMortality-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_AllCauseMortality_EG000</p><p><b>title</b>: All-cause mortality for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-AllCauseMortality\">EvidenceVariable All-cause mortality (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvents-EG000</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvents-EG000\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvents-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvents_EG000</p><p><b>title</b>: Serious Adverse Events for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvents\">EvidenceVariable Serious Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvents-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvents-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvents-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvents_EG000</p><p><b>title</b>: Other Adverse Events for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvents\">EvidenceVariable Other Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.2113</p><p><b>numberAffected</b>: 15</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-AllCauseMortality-EG001</b></p><a name=\"399874/NCT03421379-AllCauseMortality-EG001\"> </a><a name=\"hc399874/NCT03421379-AllCauseMortality-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_AllCauseMortality_EG001</p><p><b>title</b>: All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-AllCauseMortality\">EvidenceVariable All-cause mortality (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvents-EG001</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvents-EG001\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvents-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvents_EG001</p><p><b>title</b>: Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvents\">EvidenceVariable Serious Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvents-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvents-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvents-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvents_EG001</p><p><b>title</b>: Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvents\">EvidenceVariable Other Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.1857</p><p><b>numberAffected</b>: 13</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvent-0-EG000</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvent-0-EG000\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvent-0-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvent_0_EG000</p><p><b>title</b>: Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvent-0\">EvidenceVariable Vertigo positional as serious adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvent-0-EG001</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvent-0-EG001\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvent-0-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvent_0_EG001</p><p><b>title</b>: Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvent-0\">EvidenceVariable Vertigo positional as serious adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-SeriousAdverseEvent-0</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvent-0\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvent-0\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Vertigo positional as serious adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Vertigo positional as serious adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Serious Adverse Event</span>, <span title=\"Codes:\">Ear and labyrinth disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-0-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-0-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-0-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_0_EG000</p><p><b>title</b>: Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-0\">EvidenceVariable Ear pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0282</p><p><b>numberOfEvents</b>: 2</p><p><b>numberAffected</b>: 2</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-0-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-0-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-0-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_0_EG001</p><p><b>title</b>: Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-0\">EvidenceVariable Ear pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-0</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-0\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-0\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Ear pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Ear pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Ear and labyrinth disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-1-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-1-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-1-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_1_EG000</p><p><b>title</b>: Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-1\">EvidenceVariable Eye pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-1-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-1-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-1-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_1_EG001</p><p><b>title</b>: Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-1\">EvidenceVariable Eye pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-1</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-1\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-1\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Eye pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Eye pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Eye disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-2-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-2-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-2-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_2_EG000</p><p><b>title</b>: Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-2\">EvidenceVariable Eye pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-2-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-2-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-2-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_2_EG001</p><p><b>title</b>: Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-2\">EvidenceVariable Eye pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-2</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-2\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-2\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Eye pruritus as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Eye pruritus as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Eye disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-3-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-3-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-3-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_3_EG000</p><p><b>title</b>: Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-3\">EvidenceVariable Lacrimation increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-3-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-3-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-3-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_3_EG001</p><p><b>title</b>: Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-3\">EvidenceVariable Lacrimation increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-3</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-3\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-3\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Lacrimation increased as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Lacrimation increased as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Eye disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-4-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-4-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-4-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_4_EG000</p><p><b>title</b>: Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-4\">EvidenceVariable Diarrhoea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-4-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-4-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-4-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_4_EG001</p><p><b>title</b>: Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-4\">EvidenceVariable Diarrhoea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-4</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-4\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-4\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Diarrhoea as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Diarrhoea as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-5-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-5-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-5-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_5_EG000</p><p><b>title</b>: Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-5\">EvidenceVariable Nausea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0704</p><p><b>numberOfEvents</b>: 5</p><p><b>numberAffected</b>: 5</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-5-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-5-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-5-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_5_EG001</p><p><b>title</b>: Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-5\">EvidenceVariable Nausea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.1571</p><p><b>numberOfEvents</b>: 11</p><p><b>numberAffected</b>: 11</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-5</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-5\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-5\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Nausea as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Nausea as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-6-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-6-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-6-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_6_EG000</p><p><b>title</b>: Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-6\">EvidenceVariable Toothache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-6-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-6-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-6-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_6_EG001</p><p><b>title</b>: Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-6\">EvidenceVariable Toothache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-6</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-6\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-6\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Toothache as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Toothache as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-7-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-7-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-7-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_7_EG000</p><p><b>title</b>: Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-7\">EvidenceVariable Vomiting as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0282</p><p><b>numberOfEvents</b>: 2</p><p><b>numberAffected</b>: 2</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-7-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-7-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-7-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_7_EG001</p><p><b>title</b>: Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-7\">EvidenceVariable Vomiting as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0571</p><p><b>numberOfEvents</b>: 5</p><p><b>numberAffected</b>: 4</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-7</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-7\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-7\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Vomiting as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Vomiting as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-8-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-8-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-8-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_8_EG000</p><p><b>title</b>: Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-8\">EvidenceVariable Feeling abnormal as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-8-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-8-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-8-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_8_EG001</p><p><b>title</b>: Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-8\">EvidenceVariable Feeling abnormal as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-8</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-8\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-8\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Feeling abnormal as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Feeling abnormal as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">General disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-9-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-9-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-9-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_9_EG000</p><p><b>title</b>: Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-9\">EvidenceVariable Cystitis as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-9-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-9-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-9-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_9_EG001</p><p><b>title</b>: Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-9\">EvidenceVariable Cystitis as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-9</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-9\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-9\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Cystitis as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Cystitis as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Infections and infestations</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-10-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-10-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-10-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_10_EG000</p><p><b>title</b>: Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-10\">EvidenceVariable Blood pressure decreased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-10-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-10-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-10-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_10_EG001</p><p><b>title</b>: Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-10\">EvidenceVariable Blood pressure decreased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0286</p><p><b>numberOfEvents</b>: 2</p><p><b>numberAffected</b>: 2</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-10</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-10\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-10\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Blood pressure decreased as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Blood pressure decreased as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Investigations</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-11-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-11-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-11-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_11_EG000</p><p><b>title</b>: Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-11\">EvidenceVariable Blood pressure increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0563</p><p><b>numberOfEvents</b>: 4</p><p><b>numberAffected</b>: 4</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-11-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-11-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-11-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_11_EG001</p><p><b>title</b>: Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-11\">EvidenceVariable Blood pressure increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-11</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-11\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-11\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Blood pressure increased as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Blood pressure increased as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Investigations</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-12-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-12-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-12-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_12_EG000</p><p><b>title</b>: Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-12\">EvidenceVariable Back pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-12-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-12-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-12-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_12_EG001</p><p><b>title</b>: Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-12\">EvidenceVariable Back pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-12</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-12\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-12\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Back pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Back pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Musculoskeletal and connective tissue disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-13-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-13-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-13-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_13_EG000</p><p><b>title</b>: Headache as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-13\">EvidenceVariable Headache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-13-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-13-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-13-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_13_EG001</p><p><b>title</b>: Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-13\">EvidenceVariable Headache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-13</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-13\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-13\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Headache as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Headache as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Nervous system disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-14-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-14-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-14-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_14_EG000</p><p><b>title</b>: Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-14\">EvidenceVariable Nasal congestion as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-14-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-14-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-14-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_14_EG001</p><p><b>title</b>: Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-14\">EvidenceVariable Nasal congestion as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-14</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-14\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-14\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Nasal congestion as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Nasal congestion as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-15-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-15-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-15-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_15_EG000</p><p><b>title</b>: Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-15\">EvidenceVariable Nasal pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-15-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-15-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-15-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_15_EG001</p><p><b>title</b>: Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-15\">EvidenceVariable Nasal pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-15</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-15\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-15\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Nasal pruritus as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Nasal pruritus as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-16-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-16-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-16-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_16_EG000</p><p><b>title</b>: Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-16\">EvidenceVariable Oropharyngeal pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-16-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-16-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-16-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_16_EG001</p><p><b>title</b>: Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-16\">EvidenceVariable Oropharyngeal pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-16</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-16\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-16\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Oropharyngeal pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Oropharyngeal pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-17-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-17-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-17-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_17_EG000</p><p><b>title</b>: Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-17\">EvidenceVariable Rhinalgia as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0845</p><p><b>numberOfEvents</b>: 6</p><p><b>numberAffected</b>: 6</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-17-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-17-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-17-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_17_EG001</p><p><b>title</b>: Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-17\">EvidenceVariable Rhinalgia as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-17</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-17\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-17\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Rhinalgia as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Rhinalgia as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-18-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-18-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-18-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_18_EG000</p><p><b>title</b>: Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-18\">EvidenceVariable Cold sweat as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-18-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-18-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-18-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_18_EG001</p><p><b>title</b>: Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-18\">EvidenceVariable Cold sweat as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-18</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-18\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-18\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Cold sweat as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Cold sweat as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Skin and subcutaneous tissue disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-19-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-19-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-19-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_19_EG000</p><p><b>title</b>: Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-19\">EvidenceVariable Hot flush as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-19-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-19-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-19-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_19_EG001</p><p><b>title</b>: Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-19\">EvidenceVariable Hot flush as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-19</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-19\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-19\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Hot flush as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Hot flush as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Vascular disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-20-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-20-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-20-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_20_EG000</p><p><b>title</b>: Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-20\">EvidenceVariable Hypertension as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-20-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-20-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-20-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_20_EG001</p><p><b>title</b>: Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-20\">EvidenceVariable Hypertension as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-20</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-20\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-20\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Hypertension as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Hypertension as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Vascular disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-21-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-21-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-21-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_21_EG000</p><p><b>title</b>: Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-21\">EvidenceVariable Peripheral coldness as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-21-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-21-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-21-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_21_EG001</p><p><b>title</b>: Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-21\">EvidenceVariable Peripheral coldness as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-21</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-21\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-21\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Peripheral coldness as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Peripheral coldness as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Vascular disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote></div>"^^rdf:XMLLiteral ] ] ; # fhir:contained ( [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-AllCauseMortality" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "All-cause mortality (timeframe for NCT03421379)" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "All-cause mortality" ] ] ] ; fhir:handling [ fhir:v "boolean" ] ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-SeriousAdverseEvents" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Serious Adverse Events (timeframe for NCT03421379)" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Serious Adverse Events" ] ] ] ; fhir:handling [ fhir:v "boolean" ] ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvents" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Other Adverse Events (timeframe for NCT03421379)" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Other Adverse Events" ] ] ] ; fhir:handling [ fhir:v "boolean" ] ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-AllCauseMortality-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_AllCauseMortality_EG000" ] ; fhir:title [ fhir:v "All-cause mortality for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-AllCauseMortality> ; fhir:reference [ fhir:v "#NCT03421379-AllCauseMortality" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-SeriousAdverseEvents-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_SeriousAdverseEvents_EG000" ] ; fhir:title [ fhir:v "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-SeriousAdverseEvents> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvents" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvents-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvents_EG000" ] ; fhir:title [ fhir:v "Other Adverse Events for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvents> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvents" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.2113 ] ] ; fhir:numberAffected [ fhir:v "15"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-AllCauseMortality-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_AllCauseMortality_EG001" ] ; fhir:title [ fhir:v "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-AllCauseMortality> ; fhir:reference [ fhir:v "#NCT03421379-AllCauseMortality" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-SeriousAdverseEvents-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_SeriousAdverseEvents_EG001" ] ; fhir:title [ fhir:v "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-SeriousAdverseEvents> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvents" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvents-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvents_EG001" ] ; fhir:title [ fhir:v "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvents> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvents" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.1857 ] ] ; fhir:numberAffected [ fhir:v "13"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-SeriousAdverseEvent-0-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_SeriousAdverseEvent_0_EG000" ] ; fhir:title [ fhir:v "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-SeriousAdverseEvent-0> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvent-0" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-SeriousAdverseEvent-0-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_SeriousAdverseEvent_0_EG001" ] ; fhir:title [ fhir:v "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-SeriousAdverseEvent-0> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvent-0" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-SeriousAdverseEvent-0" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Vertigo positional as serious adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Vertigo positional as serious adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Serious Adverse Event" ] ] [ fhir:text [ fhir:v "Ear and labyrinth disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-0-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_0_EG000" ] ; fhir:title [ fhir:v "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-0> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-0" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0282 ] ] ; fhir:numberOfEvents [ fhir:v "2"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "2"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-0-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_0_EG001" ] ; fhir:title [ fhir:v "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-0> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-0" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-0" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Ear pain as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Ear pain as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Ear and labyrinth disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-1-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_1_EG000" ] ; fhir:title [ fhir:v "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-1> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-1" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-1-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_1_EG001" ] ; fhir:title [ fhir:v "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-1> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-1" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-1" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Eye pain as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Eye pain as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Eye disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-2-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_2_EG000" ] ; fhir:title [ fhir:v "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-2> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-2" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-2-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_2_EG001" ] ; fhir:title [ fhir:v "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-2> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-2" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-2" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Eye pruritus as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Eye pruritus as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Eye disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-3-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_3_EG000" ] ; fhir:title [ fhir:v "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-3> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-3" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-3-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_3_EG001" ] ; fhir:title [ fhir:v "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-3> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-3" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-3" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Lacrimation increased as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Lacrimation increased as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Eye disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-4-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_4_EG000" ] ; fhir:title [ fhir:v "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-4> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-4" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-4-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_4_EG001" ] ; fhir:title [ fhir:v "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-4> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-4" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-4" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Diarrhoea as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Diarrhoea as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Gastrointestinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-5-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_5_EG000" ] ; fhir:title [ fhir:v "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-5> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-5" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0704 ] ] ; fhir:numberOfEvents [ fhir:v "5"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "5"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-5-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_5_EG001" ] ; fhir:title [ fhir:v "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-5> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-5" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.1571 ] ] ; fhir:numberOfEvents [ fhir:v "11"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "11"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-5" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Nausea as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Nausea as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Gastrointestinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-6-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_6_EG000" ] ; fhir:title [ fhir:v "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-6> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-6" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-6-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_6_EG001" ] ; fhir:title [ fhir:v "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-6> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-6" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-6" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Toothache as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Toothache as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Gastrointestinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-7-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_7_EG000" ] ; fhir:title [ fhir:v "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-7> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-7" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0282 ] ] ; fhir:numberOfEvents [ fhir:v "2"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "2"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-7-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_7_EG001" ] ; fhir:title [ fhir:v "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-7> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-7" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0571 ] ] ; fhir:numberOfEvents [ fhir:v "5"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "4"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-7" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Vomiting as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Vomiting as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Gastrointestinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-8-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_8_EG000" ] ; fhir:title [ fhir:v "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-8> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-8" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-8-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_8_EG001" ] ; fhir:title [ fhir:v "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-8> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-8" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-8" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Feeling abnormal as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Feeling abnormal as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "General disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-9-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_9_EG000" ] ; fhir:title [ fhir:v "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-9> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-9" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-9-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_9_EG001" ] ; fhir:title [ fhir:v "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-9> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-9" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-9" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Cystitis as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Cystitis as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Infections and infestations" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-10-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_10_EG000" ] ; fhir:title [ fhir:v "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-10> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-10" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-10-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_10_EG001" ] ; fhir:title [ fhir:v "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-10> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-10" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0286 ] ] ; fhir:numberOfEvents [ fhir:v "2"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "2"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-10" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Blood pressure decreased as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Blood pressure decreased as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Investigations" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-11-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_11_EG000" ] ; fhir:title [ fhir:v "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-11> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-11" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0563 ] ] ; fhir:numberOfEvents [ fhir:v "4"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "4"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-11-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_11_EG001" ] ; fhir:title [ fhir:v "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-11> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-11" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-11" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Blood pressure increased as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Blood pressure increased as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Investigations" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-12-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_12_EG000" ] ; fhir:title [ fhir:v "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-12> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-12" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-12-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_12_EG001" ] ; fhir:title [ fhir:v "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-12> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-12" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-12" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Back pain as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Back pain as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Musculoskeletal and connective tissue disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-13-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_13_EG000" ] ; fhir:title [ fhir:v "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-13> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-13" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-13-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_13_EG001" ] ; fhir:title [ fhir:v "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-13> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-13" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-13" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Headache as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Headache as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Nervous system disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-14-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_14_EG000" ] ; fhir:title [ fhir:v "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-14> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-14" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-14-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_14_EG001" ] ; fhir:title [ fhir:v "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-14> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-14" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-14" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Nasal congestion as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Nasal congestion as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Respiratory, thoracic and mediastinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-15-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_15_EG000" ] ; fhir:title [ fhir:v "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-15> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-15" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-15-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_15_EG001" ] ; fhir:title [ fhir:v "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-15> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-15" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-15" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Nasal pruritus as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Nasal pruritus as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Respiratory, thoracic and mediastinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-16-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_16_EG000" ] ; fhir:title [ fhir:v "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-16> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-16" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0141 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-16-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_16_EG001" ] ; fhir:title [ fhir:v "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-16> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-16" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-16" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Oropharyngeal pain as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Oropharyngeal pain as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Respiratory, thoracic and mediastinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-17-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_17_EG000" ] ; fhir:title [ fhir:v "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-17> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-17" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0845 ] ] ; fhir:numberOfEvents [ fhir:v "6"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "6"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-17-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_17_EG001" ] ; fhir:title [ fhir:v "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-17> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-17" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-17" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Rhinalgia as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Rhinalgia as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Respiratory, thoracic and mediastinal disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-18-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_18_EG000" ] ; fhir:title [ fhir:v "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-18> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-18" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-18-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_18_EG001" ] ; fhir:title [ fhir:v "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-18> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-18" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-18" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Cold sweat as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Cold sweat as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Skin and subcutaneous tissue disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-19-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_19_EG000" ] ; fhir:title [ fhir:v "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-19> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-19" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-19-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_19_EG001" ] ; fhir:title [ fhir:v "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-19> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-19" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-19" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Hot flush as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Hot flush as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Vascular disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-20-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_20_EG000" ] ; fhir:title [ fhir:v "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-20> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-20" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-20-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_20_EG001" ] ; fhir:title [ fhir:v "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-20> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-20" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-20" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Hypertension as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Hypertension as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Vascular disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-21-EG000" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_21_EG000" ] ; fhir:title [ fhir:v "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Nasal Powder" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 3 mg glucagon nasal powder was administered intranasally" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-21> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-21" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v "0"^^xsd:decimal ] ] ; fhir:numberOfEvents [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "0"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "71"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:Evidence ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-21-EG001" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence> ] ) ] ; fhir:name [ fhir:v "NCT03421379_OtherAdverseEvent_21_EG001" ] ; fhir:title [ fhir:v "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ; fhir:status [ fhir:v "active" ] ; ( fhir:variableDefinition [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ ( fhir:note [ fhir:text [ fhir:v "All randomized participants who received at least one dose of study drug." ] ] ) ; fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l <#NCT03421379-OtherAdverseEvent-21> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-21" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ] ] ) ; ( fhir:statistic [ fhir:statisticType [ fhir:text [ fhir:v "Percentage" ] ] ; fhir:quantity [ fhir:value [ fhir:v 0.0143 ] ] ; fhir:numberOfEvents [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:numberAffected [ fhir:v "1"^^xsd:nonNegativeInteger ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "70"^^xsd:nonNegativeInteger ] ] ] ) ] [ a fhir:EvidenceVariable ; fhir:id [ fhir:v "NCT03421379-OtherAdverseEvent-21" ] ; fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition> ] ) ] ; fhir:title [ fhir:v "Peripheral coldness as other adverse event" ] ; fhir:status [ fhir:v "active" ] ; fhir:definition [ fhir:concept [ fhir:text [ fhir:v "Peripheral coldness as other adverse event" ] ] ] ; ( fhir:definitionModifier [ fhir:code [ fhir:text [ fhir:v "Adverse event assessment type" ] ] ; fhir:value [ a fhir:CodeableConcept ; ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/definition-method"^^xsd:anyURI ; fhir:l <http://hl7.org/fhir/definition-method> ] ; fhir:code [ fhir:v "systematic-assessment" ] ; fhir:display [ fhir:v "Systematic Assessment" ] ] ) ] ] [ fhir:code [ fhir:text [ fhir:v "Source Vocabulary for Adverse Event Definition" ] ] ; fhir:value [ a fhir:CodeableConcept ; fhir:text [ fhir:v "MedDRA 18.1" ] ] ] ) ; fhir:handling [ fhir:v "boolean" ] ; ( fhir:classifier [ fhir:text [ fhir:v "Other Adverse Event" ] ] [ fhir:text [ fhir:v "Vascular disorders" ] ] ) ; fhir:timing [ fhir:text [ fhir:v "From Baseline to End of Follow-up (Up to 2 Months)" ] ] ] ) ; # fhir:url [ fhir:v "https://fevir.net/resources/Composition/399874"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/Composition/399874> ] ; # fhir:identifier ( [ fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ; fhir:l <http://terminology.hl7.org/CodeSystem/v2-0203> ] ; fhir:code [ fhir:v "ACSN" ] ; fhir:display [ fhir:v "Accession ID" ] ] ) ; fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FOI"^^xsd:anyURI ; fhir:l <https://fevir.net/FOI> ] ; fhir:value [ fhir:v "399874" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ; fhir:l <https://fevir.net/FLI> ] ; fhir:value [ fhir:v "NCT03421379-adverse-events-report" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "OutcomeMeasureReport" ] ; fhir:display [ fhir:v "OutcomeMeasureReport" ] ] ) ; fhir:text [ fhir:v "Outcome Measure Report" ] ] ; # fhir:date [ fhir:v "2025-12-11T20:35:21.032Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:display [ fhir:v "[No author listed.]" ] ] ) ; # fhir:title [ fhir:v "Adverse Events Report for NCT03421379"] ; # fhir:custodian [ fhir:l fhir:Organization/118079 ; fhir:reference [ fhir:v "Organization/118079" ] ; fhir:type [ fhir:v "Organization"^^xsd:anyURI ; fhir:l fhir:Organization ] ; fhir:display [ fhir:v "Computable Publishing LLC" ] ] ; # fhir:relatesTo ( [ fhir:type [ fhir:v "cite-as" ] ; fhir:target [ a fhir:Markdown ; fhir:v "Adverse Events Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399874. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399874. Computable resource at: https://fevir.net/resources/Composition/399874#json." ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "Events Frequency Threshold" ] ; fhir:code [ fhir:text [ fhir:v "EventsFrequencyThreshold" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">0%</div>"^^rdf:XMLLiteral ] ] ] [ fhir:title [ fhir:v "Events Time Frame" ] ; fhir:code [ fhir:text [ fhir:v "EventsTimeFrame" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">From Baseline to End of Follow-up (Up to 2 Months)</div>"^^rdf:XMLLiteral ] ] ] [ fhir:title [ fhir:v "Events Description" ] ; fhir:code [ fhir:text [ fhir:v "EventsDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug.</div>"^^rdf:XMLLiteral ] ] ] [ fhir:title [ fhir:v "Glucagon Nasal Powder" ] ; fhir:code [ fhir:text [ fhir:v "EG000 Glucagon Nasal Powder" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Event Group Description" ] ; fhir:code [ fhir:text [ fhir:v "EventGroupDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"^^rdf:XMLLiteral ] ] ] ) ] [ fhir:title [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:code [ fhir:text [ fhir:v "EG001 Glucagon Hydrochloride Solution" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Event Group Description" ] ; fhir:code [ fhir:text [ fhir:v "EventGroupDescription" ] ] ; fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"^^rdf:XMLLiteral ] ] ] ) ] [ fhir:title [ fhir:v "Total Mortality" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ; fhir:text [ fhir:v "Total Mortality" ] ] ; fhir:focus [ fhir:l <#NCT03421379-AllCauseMortality> ; fhir:reference [ fhir:v "#NCT03421379-AllCauseMortality" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "All-cause mortality (timeframe for NCT03421379)" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-AllCauseMortality-EG000> ; fhir:reference [ fhir:v "#NCT03421379-AllCauseMortality-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "All-cause mortality for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-AllCauseMortality-EG001> ; fhir:reference [ fhir:v "#NCT03421379-AllCauseMortality-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Total Serious Events" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ; fhir:text [ fhir:v "Total Serious Events" ] ] ; fhir:focus [ fhir:l <#NCT03421379-SeriousAdverseEvents> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvents" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Serious Adverse Events (timeframe for NCT03421379)" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-SeriousAdverseEvents-EG000> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvents-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-SeriousAdverseEvents-EG001> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvents-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Total Other Events" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ; fhir:text [ fhir:v "Total Other Events" ] ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvents> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvents" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Other Adverse Events (timeframe for NCT03421379)" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvents-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvents-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Other Adverse Events for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvents-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvents-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Serious Event List" ] ; fhir:code [ fhir:text [ fhir:v "SeriousEventList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Vertigo positional" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-SeriousAdverseEvent-0> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvent-0" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Vertigo positional as serious adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-SeriousAdverseEvent-0-EG000> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvent-0-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-SeriousAdverseEvent-0-EG001> ; fhir:reference [ fhir:v "#NCT03421379-SeriousAdverseEvent-0-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] ) ] [ fhir:title [ fhir:v "Other Event List" ] ; fhir:code [ fhir:text [ fhir:v "OtherEventList" ] ] ; ( fhir:section [ fhir:title [ fhir:v "Ear pain" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-0> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-0" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Ear pain as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-0-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-0-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-0-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-0-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Eye pain" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-1> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-1" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Eye pain as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-1-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-1-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-1-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-1-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Eye pruritus" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-2> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-2" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Eye pruritus as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-2-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-2-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-2-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-2-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Lacrimation increased" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-3> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-3" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Lacrimation increased as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-3-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-3-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-3-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-3-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Diarrhoea" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-4> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-4" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Diarrhoea as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-4-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-4-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-4-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-4-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Nausea" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-5> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-5" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Nausea as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-5-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-5-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-5-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-5-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Toothache" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-6> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-6" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Toothache as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-6-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-6-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-6-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-6-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Vomiting" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-7> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-7" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Vomiting as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-7-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-7-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-7-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-7-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Feeling abnormal" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-8> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-8" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Feeling abnormal as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-8-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-8-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-8-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-8-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Cystitis" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-9> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-9" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Cystitis as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-9-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-9-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-9-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-9-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Blood pressure decreased" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-10> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-10" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Blood pressure decreased as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-10-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-10-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-10-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-10-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Blood pressure increased" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-11> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-11" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Blood pressure increased as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-11-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-11-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-11-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-11-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Back pain" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-12> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-12" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Back pain as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-12-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-12-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-12-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-12-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Headache" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-13> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-13" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Headache as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-13-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-13-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-13-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-13-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Nasal congestion" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-14> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-14" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Nasal congestion as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-14-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-14-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-14-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-14-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Nasal pruritus" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-15> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-15" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Nasal pruritus as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-15-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-15-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-15-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-15-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Oropharyngeal pain" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-16> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-16" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Oropharyngeal pain as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-16-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-16-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-16-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-16-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Rhinalgia" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-17> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-17" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Rhinalgia as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-17-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-17-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-17-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-17-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Cold sweat" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-18> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-18" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Cold sweat as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-18-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-18-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-18-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-18-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Hot flush" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-19> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-19" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Hot flush as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-19-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-19-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-19-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-19-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Hypertension" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-20> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-20" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Hypertension as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-20-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-20-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-20-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-20-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] [ fhir:title [ fhir:v "Peripheral coldness" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ; fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ; fhir:code [ fhir:v "results" ] ; fhir:display [ fhir:v "Results" ] ] ) ] ; fhir:focus [ fhir:l <#NCT03421379-OtherAdverseEvent-21> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-21" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:display [ fhir:v "Peripheral coldness as other adverse event" ] ] ; ( fhir:entry [ fhir:l <#NCT03421379-OtherAdverseEvent-21-EG000> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-21-EG000" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379" ] ] [ fhir:l <#NCT03421379-OtherAdverseEvent-21-EG001> ; fhir:reference [ fhir:v "#NCT03421379-OtherAdverseEvent-21-EG001" ] ; fhir:type [ fhir:v "Evidence"^^xsd:anyURI ; fhir:l fhir:Evidence ] ; fhir:display [ fhir:v "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379" ] ] ) ] ) ] ) . #
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3.
Generated
2026-01-13
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change